Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as ...

Novo Nordisk's shares fell on news of a clinical success from its biggest rival. As a result, it could lose market share in an important area. However, there are still strong reasons to invest in ...